Maze Therapeutics, Inc.’s MAZE share price has dipped by 5.27%, which has investors questioning if this is right time to buy.

In the sprawling, ever-expanding universe of technology, it's easy to get lost in the labyrinth of new developments, shiny ...

Maze Therapeutics, Inc.’s MAZE share price has surged by 8.56%, which has investors questioning if this is right time to sell ...

German coalition disagrees on AI, tech sovereignty, and notes from the Amsterdam fibre conference ...

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for ...